Latest Pharma Insights
Agilent Pays $950M for Biocare Medical To Expand Pathology Reach
The acquisition adds an immunohistochemistry antibody, reagent and instrument portfolio to Agilent's pathology offering, expanding its clinical and research lab client groups.
Medtech Insight - March 11, 2026
The acquisition adds an immunohistochemistry antibody, reagent and instrument portfolio to Agilent's pathology offering, expanding its clinical and research lab client groups.
Medtech Insight - March 11, 2026
Genentech Targets Biocon In USITC Case Over Perjeta Biosimilar Imports
Genentech has asked the US International Trade Commission to investigate Biocon and related entities over alleged infringement tied to pertuzumab biosimilars, seeking remedies that could block imports into the US.
Generics Bulletin - March 11, 2026
Genentech has asked the US International Trade Commission to investigate Biocon and related entities over alleged infringement tied to pertuzumab biosimilars, seeking remedies that could block imports into the US.
Generics Bulletin - March 11, 2026
The Game Of Balancing Green Regulations While Keeping Off-Patent Drug Investment In Europe
In the second part of our exclusive interview with Medicines for Europe leaders, Generics Bulletin delves into medicinal product regulation by environmental and chemical agencies, and the need to maintain the historical off-patent drug heritage in Europe.
Generics Bulletin - March 11, 2026
In the second part of our exclusive interview with Medicines for Europe leaders, Generics Bulletin delves into medicinal product regulation by environmental and chemical agencies, and the need to maintain the historical off-patent drug heritage in Europe.
Generics Bulletin - March 11, 2026
EU Notified Bodies Warn MDR/IVDR Amendments Will Deliver Lower Levels Of Patient Safety
The public consultation on the European Commission’s proposed revision of the MDR and IVDR has been extended to accommodate late delivery of translated texts. EU notified bodies’ group TEAM-NB says the proposals need more balance to ensure the resulting regulations do not do more harm than good.
Medtech Insight - March 11, 2026
The public consultation on the European Commission’s proposed revision of the MDR and IVDR has been extended to accommodate late delivery of translated texts. EU notified bodies’ group TEAM-NB says the proposals need more balance to ensure the resulting regulations do not do more harm than good.
Medtech Insight - March 11, 2026
Excited About AI, Skeptical Of The Price Tag: Seed Investors Sound Off
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
In Vivo - March 11, 2026
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
In Vivo - March 11, 2026
Biocon And Cipla Build On Teva’s First Generic Saxenda Launch
Biocon’s FDA approval and Cipla’s US launch – via partner Orbicular – add momentum to the early generic market for Novo Nordisk’s Saxenda.
Generics Bulletin - March 11, 2026
Biocon’s FDA approval and Cipla’s US launch – via partner Orbicular – add momentum to the early generic market for Novo Nordisk’s Saxenda.
Generics Bulletin - March 11, 2026
In Brief: Jacobio/AZ’s JAB-23E73 Reports First Clinical Results For Pan-KRAS Inhibitors
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Scrip - March 11, 2026
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Scrip - March 11, 2026
As Refund Claims Mount, Interest On IEEPA Tariff Payments Equals $650M A Month, $10Bn For 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
Henkel Buys Not Your Mother’s, Aveeno Collaborates With Mayo Clinic; Beauty Deals Roundup
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
In Brief: Jacobio/AZ’s JAB-23E73 Reports First Clinical Results For Pan-KRAS Inhibitors
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Scrip - March 11, 2026
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Scrip - March 11, 2026
Agilent Pays $950M for Biocare Medical To Expand Pathology Reach
The acquisition adds an immunohistochemistry antibody, reagent and instrument portfolio to Agilent's pathology offering, expanding its clinical and research lab client groups.
Medtech Insight - March 11, 2026
The acquisition adds an immunohistochemistry antibody, reagent and instrument portfolio to Agilent's pathology offering, expanding its clinical and research lab client groups.
Medtech Insight - March 11, 2026
EU Notified Bodies Warn MDR/IVDR Amendments Will Deliver Lower Levels Of Patient Safety
The public consultation on the European Commission’s proposed revision of the MDR and IVDR has been extended to accommodate late delivery of translated texts. EU notified bodies’ group TEAM-NB says the proposals need more balance to ensure the resulting regulations do not do more harm than good.
Medtech Insight - March 11, 2026
The public consultation on the European Commission’s proposed revision of the MDR and IVDR has been extended to accommodate late delivery of translated texts. EU notified bodies’ group TEAM-NB says the proposals need more balance to ensure the resulting regulations do not do more harm than good.
Medtech Insight - March 11, 2026
As Refund Claims Mount, Interest On IEEPA Tariff Payments Equals $650M A Month, $10Bn For 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
Henkel Buys Not Your Mother’s, Aveeno Collaborates With Mayo Clinic; Beauty Deals Roundup
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Genentech Targets Biocon In USITC Case Over Perjeta Biosimilar Imports
Genentech has asked the US International Trade Commission to investigate Biocon and related entities over alleged infringement tied to pertuzumab biosimilars, seeking remedies that could block imports into the US.
Generics Bulletin - March 11, 2026
Genentech has asked the US International Trade Commission to investigate Biocon and related entities over alleged infringement tied to pertuzumab biosimilars, seeking remedies that could block imports into the US.
Generics Bulletin - March 11, 2026
The Game Of Balancing Green Regulations While Keeping Off-Patent Drug Investment In Europe
In the second part of our exclusive interview with Medicines for Europe leaders, Generics Bulletin delves into medicinal product regulation by environmental and chemical agencies, and the need to maintain the historical off-patent drug heritage in Europe.
Generics Bulletin - March 11, 2026
In the second part of our exclusive interview with Medicines for Europe leaders, Generics Bulletin delves into medicinal product regulation by environmental and chemical agencies, and the need to maintain the historical off-patent drug heritage in Europe.
Generics Bulletin - March 11, 2026
Biocon And Cipla Build On Teva’s First Generic Saxenda Launch
Biocon’s FDA approval and Cipla’s US launch – via partner Orbicular – add momentum to the early generic market for Novo Nordisk’s Saxenda.
Generics Bulletin - March 11, 2026
Biocon’s FDA approval and Cipla’s US launch – via partner Orbicular – add momentum to the early generic market for Novo Nordisk’s Saxenda.
Generics Bulletin - March 11, 2026
Excited About AI, Skeptical Of The Price Tag: Seed Investors Sound Off
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
In Vivo - March 11, 2026
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
In Vivo - March 11, 2026